| Aeglea BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biotechnology company developing human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Co.'s development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and ACN00177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. Co.'s preclinical pipeline includes AEB5100 Program in Cystinuria. We show 23 historical shares outstanding datapoints in our AGLE shares outstanding history coverage, used to compute AGLE market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AGLE market cap history over the course of time is important for investors
interested in comparing AGLE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AGLE versus a peer is one thing; comparing
AGLE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AGLE can fluctuate over the course of history.
With this page we aim to empower investors researching AGLE by allowing them to research the AGLE market cap history.